Ride the megatrend with "Gufic Biosciences Limited" (GBSL), an India-based company operating in four business segments: formulations, bulk drugs, consumer products and agro products.
Fundamentals supporting it be a potential multibagger:
The Indian healthcare sector is expected to reach US$ 372 billion by 2024, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. Gufic bio is one of the company to get benefit of the megatrend.
Gufic Biosciences has done good performance over a period of time,
It has a Debt to Equity ratio of 1.16 , which is a strong indication for the company.
Its cash from the operating activity was Rs 45.69 Cr.
Gufic Biosciences have a healthy ROE of 26.70 %
It has a high promoter holding of 65.75%.
Company has good cash flow
Technicals:
Cup and handle pattern breakout with significant vol
MACD above signal and center
RSI Indicating price strength
"All you need for a lifetime of successful investing is a few big winners, and the pluses from those will overwhelm the minuses from the stocks that don’t work out.” – Peter Lynch
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.